세계의 암 통증 관리 시장 : 약제 유형별, 투여 경로별, 용도별, 최종 용도별-예측(2025-2030년)

The Cancer Pain Management Market was valued at USD 7.42 billion in 2023, expected to reach USD 7.86 billion in 2024, and is projected to grow at a CAGR of 6.09%, to USD 11.23 billion by 2030.

The Cancer Pain Management industry encompasses a wide range of treatments and technologies aimed at alleviating pain in individuals with cancer. This scope includes pharmacological treatments such as opioids, NSAIDs, and adjuvant therapies, along with non-pharmacological methods like acupuncture, physiotherapy, and neuromodulation. The necessity for cancer pain management arises from the severe, often debilitating pain that can accompany the disease and its treatments, impacting patients' quality of life. The application of pain management options extends beyond palliative care, offering enhanced life quality and functional capabilities for patients throughout various cancer treatment stages. End-use scopes are broad, including hospitals, ambulatory surgical centers, specialty clinics, and home care settings. Market growth is heavily influenced by the rising prevalence of cancer, advancements in pain management technologies, and increasing patient awareness and demand for quality of life improvements.

Key growth factors include technological advancements and the development of new therapeutics aimed at more precise and effective pain relief, along with favorable government initiatives and investments in healthcare infrastructure. Potential opportunities lie in emerging markets where access to effective pain management is improving and the adoption of integrative pain management approaches is increasing. Recommendations to capture these opportunities involve investing in innovative research and expanding partnerships with healthcare providers for comprehensive pain management solutions. However, the market faces limitations including regulatory challenges, high costs associated with advanced therapies, and the opioid crisis, which limits opioid-based management strategies. Challenges also stem from barriers to access in low and middle-income countries and the complexity of achieving personalized pain management solutions.

Innovation and research should prioritize personalized medicine, non-opioid alternatives, and holistic approaches integrating psychological support. By focusing on these areas, companies can enhance business growth and market differentiation. The nature of the market is dynamic and multidisciplinary, requiring continuous adaptation and integration of novel insights into comprehensive cancer care strategies. By aligning with evolving patient needs and regulatory frameworks, stakeholders in the cancer pain management market can effectively address the diverse challenges and opportunities within this critical healthcare segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Pain Management Market

The Cancer Pain Management Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic pain and lifestyle disorders worldwide
  • Increasing geriatric population and need for pain-reducing therapies
• Market Restraints
  • Issues associated with product recalls
• Market Opportunities
  • Ongoing product development activities and rising FDA approvals of new products
  • Government funding supporting cancer pain treatments
• Market Challenges
  • Adverse effects associated with cancer pain management drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Pain Management Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Pain Management Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Pain Management Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Pain Management Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Pain Management Market

A detailed market share analysis in the Cancer Pain Management Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Pain Management Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Pain Management Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Pain Management Market

A strategic analysis of the Cancer Pain Management Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Pain Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aegis Therapeutics, LLC, Aptinyx Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Glaxosmithkline PLC, Grunenthal Group, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Trevena Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Pain Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Nerve Blockers, Non-Opioids, and Opioids. The Non-Opioids is further studied across Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The Opioids is further studied across Fentanyl and Morphine.
• Based on Route of Administration, market is studied across Oral and Parental.
• Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
• Based on End-Use, market is studied across Home care, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic pain and lifestyle disorders worldwide
    • 5.1.1.2. Increasing geriatric population and need for pain-reducing therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing product development activities and rising FDA approvals of new products
    • 5.1.3.2. Government funding supporting cancer pain treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with cancer pain management drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing applicability of opioids to treat cancer pain
  • 5.2.2. Route of Administration: Growing availability of oral medications for cancer pain management
  • 5.2.3. Application: Emerging penetration of cancer pain management solutions for breast cancer
  • 5.2.4. End-Use: Elevating usage of cancer pain drugs in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Pain Management Market, by Drug Type

• 6.1. Introduction
• 6.2. Nerve Blockers
• 6.3. Non-Opioids
  • 6.3.1. Acetaminophen
  • 6.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.4. Opioids
  • 6.4.1. Fentanyl
  • 6.4.2. Morphine

7. Cancer Pain Management Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parental

8. Cancer Pain Management Market, by Application

• 8.1. Introduction
• 8.2. Blood Cancer
• 8.3. Breast Cancer
• 8.4. Colorectal Cancer
• 8.5. Lung Cancer
• 8.6. Prostate Cancer

9. Cancer Pain Management Market, by End-Use

• 9.1. Introduction
• 9.2. Home care
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Americas Cancer Pain Management Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer Pain Management Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Pain Management Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FDA Approves Non-Opioid Painkiller for Mild-to-Moderate Pain
  • 13.3.2. Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
  • 13.3.3. Esteve and Medtronic are Collaborating to Address Cancer Pain Patients' Needs
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Aegis Therapeutics, LLC
• 4. Aptinyx Inc.
• 5. Astellas Pharma Inc.
• 6. Bausch Health Companies Inc.
• 7. Baxter International Inc.
• 8. Bayer AG
• 9. Biogen Inc.
• 10. Boehringer Ingelheim International GmbH
• 11. Eisai Co., Ltd.
• 12. Eli Lilly and Company
• 13. Glaxosmithkline PLC
• 14. Grunenthal Group
• 15. Johnson & Johnson Services, Inc.
• 16. Merck & Co. Inc.
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Regeneron Pharmaceuticals Inc.
• 20. Sanofi SA
• 21. Scilex Pharmaceuticals
• 22. Teva Pharmaceutical Industries Ltd.
• 23. Trevena Inc.